7Baggers
 ABL Bio’s Grabody lands second $2.6B deal, this time with Lilly  BioWorld MedTech Thu, 13 Nov 2025 21:50:47 GMT
 novabridge(新桥生物) 사전 ipo 요약: 갱신된 i-mab?  Smartkarma Tue, 04 Nov 2025 22:31:17 GMT
 relative strength of i mab depositary receipt in sector analysis  newser.com Sun, 02 Nov 2025 17:01:34 GMT
 i-mab's (imab) sell (d-) rating reaffirmed at weiss ratings  MarketBeat Sat, 01 Nov 2025 17:19:25 GMT
 i-mab to release 1h 2024 financial results on august 28, 2024  MarketScreener Sat, 01 Nov 2025 06:11:53 GMT

I-Mab
(NASDAQ:IMAB) 

IMAB stock logo

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. It is developing Felzartamab (TJ202), a CD38 antibody th...

Founded: 2014
Full Time Employees: 229
CEO: Huaqiong Shen  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends